Dimensional Fund Advisors LP Has $60.75 Million Position in Catalent, Inc. (NYSE:CTLT)

Dimensional Fund Advisors LP reduced its holdings in shares of Catalent, Inc. (NYSE:CTLT) by 3.0% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,080,381 shares of the company’s stock after selling 33,619 shares during the period. Dimensional Fund Advisors LP owned 0.60% of Catalent worth $60,753,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of CTLT. Vanguard Group Inc. grew its stake in shares of Catalent by 1.1% in the 1st quarter. Vanguard Group Inc. now owns 20,405,181 shares of the company’s stock valued at $1,151,872,000 after buying an additional 218,682 shares during the period. Capital World Investors grew its stake in shares of Catalent by 6.1% in the 4th quarter. Capital World Investors now owns 19,079,994 shares of the company’s stock valued at $857,264,000 after buying an additional 1,098,474 shares during the period. Cadian Capital Management LP grew its stake in shares of Catalent by 14.3% in the 4th quarter. Cadian Capital Management LP now owns 6,064,384 shares of the company’s stock valued at $272,473,000 after buying an additional 759,600 shares during the period. Capital International Investors grew its stake in shares of Catalent by 1.2% in the 4th quarter. Capital International Investors now owns 2,994,467 shares of the company’s stock valued at $134,541,000 after buying an additional 34,856 shares during the period. Finally, Alpine Associates Management Inc. grew its stake in shares of Catalent by 3.8% in the 2nd quarter. Alpine Associates Management Inc. now owns 2,061,251 shares of the company’s stock valued at $115,904,000 after buying an additional 75,700 shares during the period.

Insiders Place Their Bets

In related news, insider David Mcerlane sold 1,994 shares of Catalent stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total value of $119,580.18. Following the sale, the insider now owns 36,304 shares of the company’s stock, valued at approximately $2,177,150.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, insider David Mcerlane sold 1,994 shares of Catalent stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $59.97, for a total value of $119,580.18. Following the sale, the insider now owns 36,304 shares of the company’s stock, valued at approximately $2,177,150.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Matti Masanovich sold 2,993 shares of Catalent stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $56.74, for a total transaction of $169,822.82. Following the completion of the sale, the chief financial officer now directly owns 33,871 shares in the company, valued at approximately $1,921,840.54. The disclosure for this sale can be found here. Insiders have sold a total of 15,403 shares of company stock valued at $902,503 in the last 90 days. 0.31% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts have recently commented on CTLT shares. Baird R W downgraded Catalent from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Robert W. Baird reaffirmed a “neutral” rating and issued a $63.50 price target on shares of Catalent in a research report on Tuesday, September 24th. Barclays raised their price target on shares of Catalent from $47.00 to $63.00 and gave the company an “equal weight” rating in a research report on Friday, June 28th. William Blair reaffirmed a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. Finally, StockNews.com initiated coverage on shares of Catalent in a research report on Thursday. They issued a “sell” rating on the stock. One research analyst has rated the stock with a sell rating and eight have issued a hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $59.83.

Catalent Price Performance

Catalent stock opened at $60.33 on Friday. Catalent, Inc. has a 52 week low of $31.80 and a 52 week high of $61.20. The company’s 50 day moving average price is $59.69 and its two-hundred day moving average price is $57.33. The company has a quick ratio of 1.96, a current ratio of 2.52 and a debt-to-equity ratio of 1.35. The stock has a market cap of $10.92 billion, a P/E ratio of -9.89, a P/E/G ratio of 2.32 and a beta of 1.15.

Catalent (NYSE:CTLT) last posted its earnings results on Thursday, August 29th. The company reported $0.57 EPS for the quarter, topping the consensus estimate of $0.44 by $0.13. Catalent had a negative net margin of 22.72% and a negative return on equity of 0.56%. The firm had revenue of $1.30 billion for the quarter, compared to analysts’ expectations of $1.23 billion. On average, equities analysts predict that Catalent, Inc. will post 0.85 earnings per share for the current year.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.